butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Coadministration of CYP3A4 inducers might lessen sufentanil levels and efficacy, perhaps precipitating withdrawal syndrome in people who've designed Bodily dependence to sufentanil. Discontinuation of concomit